COVID-19 vaccine safety and effectiveness at 3 months in institutionalized old people DOI Creative Commons

Mathilde Malignac,

A. Besseiche,

Anaïs Cloppet-Fontaine

и другие.

BMC Geriatrics, Год журнала: 2024, Номер 24(1)

Опубликована: Дек. 23, 2024

Older age and associated comorbid conditions increase the risk of severe form COVID-19 death. The SARS-CoV-2 vaccination campaign began in France December 2020 targeting institutionalized older population before having been evaluated this population. objective our study was to assess tolerability 21 days (D21) 90 after first (D90) old people. Secondary its effectiveness (mortality, hospitalization occurrence COVID) at D21 D90. People living nursing homes or long-term facilities were included 12-2020-06-2021. They divided into vaccinated unvaccinated groups. Vaccine prospectively assessed by health events D90 (local systemic side effects, geriatric syndromes, cardiovascular events). efficacy serious adverse (unscheduled all-cause mortality). mean 2595 participants 86 years, 83% received vaccine. There no significant difference between for local At D90, had significantly fewer infections (odds ratio (95% confidence interval) = 0.35 (0.22–0.58)), deaths hospitalizations (0.50 (0.31–0.81)), (0.28 (0.12–0.64)) pressure ulcers (0.38 (0.17–0.88)). In prospective cohort study, vaccine a very reassuring safety profile protective effect on COVID-19, deaths, ulcers.

Язык: Английский

Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction DOI
Ankita Saha,

Shweta Choudhary,

Priyanshu Walia

и другие.

Virology, Год журнала: 2025, Номер 604, С. 110394 - 110394

Опубликована: Янв. 11, 2025

Язык: Английский

Процитировано

1
Systemic profiling of immune responses in healthy adults vaccinated with an RBD-targeting COVID-19 mRNA vaccine DOI Creative Commons
Chao Zhou, Mengxu Sun, Xing‐Yao Huang

и другие.

hLife, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
COVID-19 vaccine safety and effectiveness at 3 months in institutionalized old people DOI Creative Commons

Mathilde Malignac,

A. Besseiche,

Anaïs Cloppet-Fontaine

и другие.

BMC Geriatrics, Год журнала: 2024, Номер 24(1)

Опубликована: Дек. 23, 2024

Older age and associated comorbid conditions increase the risk of severe form COVID-19 death. The SARS-CoV-2 vaccination campaign began in France December 2020 targeting institutionalized older population before having been evaluated this population. objective our study was to assess tolerability 21 days (D21) 90 after first (D90) old people. Secondary its effectiveness (mortality, hospitalization occurrence COVID) at D21 D90. People living nursing homes or long-term facilities were included 12-2020-06-2021. They divided into vaccinated unvaccinated groups. Vaccine prospectively assessed by health events D90 (local systemic side effects, geriatric syndromes, cardiovascular events). efficacy serious adverse (unscheduled all-cause mortality). mean 2595 participants 86 years, 83% received vaccine. There no significant difference between for local At D90, had significantly fewer infections (odds ratio (95% confidence interval) = 0.35 (0.22–0.58)), deaths hospitalizations (0.50 (0.31–0.81)), (0.28 (0.12–0.64)) pressure ulcers (0.38 (0.17–0.88)). In prospective cohort study, vaccine a very reassuring safety profile protective effect on COVID-19, deaths, ulcers.

Язык: Английский

Процитировано

0